Navigation Links
Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/14/2008

d license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists and an agreement with Genentech, Inc. in the areas of nerve growth and anti-angiogenesis.

For additional information about the company, please visit http://www.renovis.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial results, including future revenues and future operating expenses, future preclinical and clinical development, anticipated preclinical and clinical development progress, the anticipated benefits of the business combination transaction involving Evotec and Renovis, the likelihood and timing of the completion of such transaction and the plans and objectives of management are forward-looking statements and are based on management's current expectations and estimates. We may not actually achieve these plans, intentions or expectations and Renovis cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from these forward-looking statements include, but are not limited to, the risk that the conditions relating to the required regulatory clearance of the transaction might not be satisfied in a timely manner or at all, risks relating to the integration of the technologies and businesses of Evotec and Renovis, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, and
'/>"/>

SOURCE Renovis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Selexis ... for biologic drug discovery and mammalian cell line development, ... CHO-Mplus Libraries ™ will be presented at the 10th ... being held, September 8 – 10, 2014 at the ... , The following abstract will be presented during ...
(Date:7/30/2014)... Wellesley, MA (PRWEB) July 30, 2014 ... report, Global Markets for Enzymes in Industrial Applications ... to reach to nearly $7.1 billion by 2018, registering ... Maximum growth is estimated to be recorded in the ... the forecast period. , Enzyme technology has influenced almost ...
(Date:7/30/2014)... 2014 Researchers often use microelectronic devices ... such devices can do much more – perhaps ... researchers have looked to patterned assemblies of proteins ... engineering to characterize – and potentially control – ... envisioned to recreate animal and human physiological functions ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... (Amex: UPI ),a medical device company that ... dysfunctions, today reported financial,results for the third quarter of ... the third quarter of fiscal 2009 were $3.4 million ... "As we discussed in conjunction ...
... - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), announced ... Mark approval for its Neurostep(TM) System, the first ... on peripheral nerves. CE Mark represents regulatory approval ... any of the Member States of the European ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) announced today ... BioMarin marketing approval for Naglazyme(R) (galsulfase) for the treatment ... pleased to receive marketing approval for Naglazyme in Brazil ... VI patients in the world," said Stephen Aselage, Senior ...
Cached Biology Technology:Uroplasty Reports Third Quarter Fiscal 2009 Results 2Uroplasty Reports Third Quarter Fiscal 2009 Results 3Uroplasty Reports Third Quarter Fiscal 2009 Results 4Uroplasty Reports Third Quarter Fiscal 2009 Results 5Uroplasty Reports Third Quarter Fiscal 2009 Results 6Uroplasty Reports Third Quarter Fiscal 2009 Results 7Uroplasty Reports Third Quarter Fiscal 2009 Results 8Uroplasty Reports Third Quarter Fiscal 2009 Results 9Uroplasty Reports Third Quarter Fiscal 2009 Results 10Uroplasty Reports Third Quarter Fiscal 2009 Results 11Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... Chemical products, energy sources, oils, paints, and more from biomass ... thought can be obtained. Aware of this, engineer Mara Gonzlez ... as the most suitable processing techniques and technologies for refining ... organic natural resources and thus substitute them for fossil fuels ...
... This release is available in French ... resources, the National Research Council of Canada, the University ... methane-eating bacteria survive in a highly unique spring located ... Lyle Whyte, McGill University microbiologist explains that the Lost ...
... a question asked by marine scientists from the Gulf of Mexico ... and marine habitat once it has been damaged or even killed? ... may be a cheap and simple solution that can be used ... was carried out by Dr Graham Forrester, from the University of ...
Cached Biology News:Ph.D. thesis opens doors to obtaining chemical products and materials using biomass as raw material 2Ph.D. thesis opens doors to obtaining chemical products and materials using biomass as raw material 3Could life survive on Mars? Yes, expert says 2Coral transplantation the simple and cheap solution to reef restoration 2
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
... membrane-filtered isotonic and enzyme-free aqueous formulations ... agents in either Ca2+- and Mg2+-free ... Ca2+- and Mg2+-free phosphate-buffered saline for ... support substrates and each other for ...
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml ... , 0.2 ml BLT5615 glycerol stock , 1010 ... Negative Control Lysate , 50 l S-protein HRP Conjugate ...
Biology Products: